Objective: Thrombin mediates the life-threatening cerebral edema that occurs after intracerebral hemorrhage. Therefore, we examined the mechanisms of thrombin-induced injury to the blood-brain barrier (BBB) and subsequent mechanisms of BBB repair. Methods: Intracerebroventricular injection of thrombin (20U) was used to model intraventricular hemorrhage in adult rats. Results: Thrombin reduced brain microvascular endothelial cell (BMVEC) and perivascular astrocyte immunoreactivity-indicating either cell injury or death-and functionally disrupted the BBB as measured by increased water content and extravasation of sodium fluorescein and Evans blue dyes 24 hours later. Administration of nonspecific Src family kinase inhibitor (PP2) immediately after thrombin injections blocked brain edema and BBB disruption. At 7 to 14 days after thrombin injections, newborn endothelial cells and astrocytes were observed around cerebral vessels at the time when BBB permeability and cerebral water content resolved. Delayed administration of PP2 on days 2 through 6 after thrombin injections prevented resolution of the edema and abnormal BBB permeability. Interpretation: Thrombin, via its protease-activated receptors, is postulated to activate Src kinase phosphorylation of molecules that acutely injure the BBB and produce edema. Thus, acute administration of Src antagonists blocks edema. In contrast, Src blockade for 2 to 6 days after thrombin injections is postulated to prevent resolution of edema and abnormal BBB permeability in part because Src kinase proto-oncogene members stimulate proliferation of newborn BMVECs and perivascular astrocytes in the neurovascular niche that repair the damaged BBB. Thus, Src kinases not only mediate acute BBB injury but also mediate chronic BBB repair after thrombin-induced injury. ANN NEUROL 2010;67:526 -533 I ntracerebral hemorrhage (ICH) activates thrombin. 1, 2 Thrombin is the molecule that mediates the development of acute cerebral edema after ICH, as acute edema can be prevented by thrombin inhibitors.
I
ntracerebral hemorrhage (ICH) activates thrombin. 1, 2 Thrombin is the molecule that mediates the development of acute cerebral edema after ICH, as acute edema can be prevented by thrombin inhibitors. 1 After thrombin injections into caudate-putamen of adult rat brain, edema increases within several hours, peaks around the first to third day, and then declines gradually over several weeks. 3, 4 The cerebral edema changes in parallel with changes in blood-brain barrier (BBB) permeability. 4 However, the mechanisms that lead to thrombin-induced BBB disruption are unknown, as are the mechanisms responsible for the subsequent repair of the BBB. These mechanisms are the subject of this study.
The BBB is a specialized system of brain microvascular endothelial cells (BMVECs), astrocytes, basement membrane, pericytes, and neurons. 5 BMVECs are the thin layer of cells that line the interior surface of blood vessels, forming an interface between circulating blood and the brain. Complex tight junctions between adjacent endothelial cells form a physical barrier, forcing most molecular traffic to take a transcellular/transporter route across the BBB, rather than moving paracellularly through the junctions, as in most endothelial cells. [5] [6] [7] [8] Astrocytes are an important component of the BBB, enveloping Ͼ99% of BMVECs. 8 BMVECs and astrocytes influence each other's development, structure, and function. 5, 6, 9 It is not known, however, how ICH leads to BBB dysfunction and brain edema. In this study, we postulated that thrombin-induced BMVEC and astrocyte injuries would lead to disruption of the BBB and brain edema, and that the proliferation (birth) of BMVECs and astrocytes would correlate with restoration of the BBB and resolution of edema after ICH. To begin to address these hypotheses, we examined BMVECs and perivascular astrocytes during the BBB disruption and cerebral edema formation after intracerebroventricular (ICV) thrombin injections to adult rats. The time course of bromodeoxyuridine (BrdU) incorporation into BMVEC and perivascular astrocytes was then examined during the period of resolution of brain edema and normalization of BBB permeability. To test whether the proliferating BMVECs and perivascular astrocytes played a causative role in repair of the BBB, the cell cycle and Src kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo- [3,4-d] pyrimidine (PP2) was given after thrombin injections. We predicted that PP2 should prolong the edema and prolong the abnormal BBB permeability. Thrombin injections into the cerebral ventricles were performed in this study because: (1) thrombin is the cause of acute edema after ICH 1 ; (2) ventricular injections of thrombin provide a simple model of intraventricular hemorrhage that occurs in humans 3, 4, 10, 11 ; and (3) intraventricular hemorrhage in humans is associated with particularly severe brain edema and high mortality rates. 12 
Materials and Methods

Injections of Thrombin into Cerebral Ventricle
Male Sprague-Dawley rats (n ϭ 120 total), weighing 300 to 320g, were anesthetized with isoflurane (Minrad, New York, NY) and placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA). A heating blanket maintained body temperature at 37°C. Thrombin (from bovine plasma, Sigma, St. Louis, MO) was dissolved in 5l saline (20U/animal) and injected into the left cerebral ventricle (ICV, day 0) (coordinates: Ϫ0.9 anteriorposterior, Ϫ1.4 medial-lateral, Ϫ4.6 dorsal-ventral, with respect to bregma). 13 The control group received 5l saline injections (ICV). The thrombin inhibitor hirudin (20U, Sigma) was coinjected (ICV, day 0) with thrombin in some animals. Rats that received ICV thrombin without hirudin were divided into 2 groups. One group of rats received 1 intraperitoneal injection immediately (day 0) of the nonspecific Src family kinase inhibitor PP2 (1.0mg/kg, Biomol International LP, Plymouth Meeting, PA). The second group of rats received a total of 5 intraperitoneal injections of PP2, once per day, from days 2 to 6.
After closure of the operative sites, rats were allowed to recover in an incubator maintained at 37°C, and then returned to their home cages with free access to food and water. All experimental procedures were performed in accordance with National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee, University of California at Davis. All reagents were purchased from Sigma unless otherwise stated.
BrdU Administration and Sample Preparation
Please see details in Supplementary Text.
Immunohistochemistry and Cell Counting
Colocalization of rat endothelial cell antigen-1 (RECA-1) or glial fibrillary acidic protein (GFAP) immunoreactive cells with BrdU immunoreactive nuclei was examined in the lacunosum moleculare layer of the hippocampus as shown in Figure 1 . Please see details in Supplementary Text.
BBB Permeability
BBB permeability was measured using a recently developed sodium fluorescein (NF)/Evans blue (EB) technique. 14 Please see details in Supplementary Text.
Brain Water Content
Results
Effects of Thrombin on BMVECs
In sham operated rats, RECA-1 ϩ cells delineated the tube-shaped brain capillaries (Fig. 2 ). BMVEC staining with RECA-1 markedly decreased, and brain capillary shape changed at 1 day after thrombin injections. Acute PP2 administration, immediately after thrombin injec-
The lacunosum moleculare layer (LMol) is located between CA1 pyramidal neurons and the molecular layer of the dentate gyrus (MoDG) in the hippocampus. The LMol is characterized by a series of large (10 -50m diameter) blood vessels (marked with stars) that were perpendicular to the plane of these coronal sections in every animal in this study. Scale bar ‫؍‬ 500m.
tion, blocked the thrombin-induced reductions in RECA-1 immunoreactivity, and brain capillary shape changes. At 1 and 2 weeks after thrombin injections, RECA-1-stained BMVECs were often colabeled with BrdU. However, the numbers of BrdU ϩ /GFAP ϩ cells at 14 days were less than those at 7 days after thrombin injections. Some brain capillaries regained their tube shape at 7 days, and more brain capillaries regained their tube shape at 14 days after the thrombin injections.
Effects of Thrombin on Astrocytes
In sham operated rats, GFAP ϩ cells enveloped brain vessels (Fig 3) . Astrocyte staining with GFAP markedly decreased around brain vessels 24 hours after thrombin injections. PP2 administration at day 0, immediately after thrombin injection, blocked the thrombin-induced reductions in GFAP immunoreactivity. GFAP-stained astrocytes, which often were colabeled with BrdU, increased around blood vessels at 7 days and at 14 days after thrombin injections. However, the numbers of BrdU ϩ /GFAP ϩ cells at 14 days were less than those at 7 days after thrombin injections.
Effects of Thrombin on Brain NF/EB Extravasation
One day after thrombin injections, the extravasation of NF into brains of thrombin-treated rats was markedly greater than that detected in controls (Fig 4A; When coinjected with thrombin, hirudin blocked both thrombin-induced NF extravasation (see Fig 4A; Fig 4A) . Similarly, in the absence of hirudin or PP2, EB in the brains decreased from 2588.6 Ϯ 188.5ng/ml to 1441.0 Ϯ 69.1ng/ml after 7 days ( p Ͻ 0.05 for thrombin/7 days) and to 945.7 Ϯ 50.6ng/ml after 14 days ( p Ͻ 0.05 for thrombin/14 days) (see Fig 4B) . Lastly, PP2 given once a day from day 2 to day 6 blocked the alleviation of NF extravasation at 7 days after the thrombin injections (see Fig 4A; 545.7 Ϯ 17.0ng/ml [thrombin/PP2 days 2-6/7 days] vs 353.9 Ϯ 23.8ng/ml [thrombin/7 days]; p Ͻ 0.01). Similarly, PP2 given once a day from day 2 to day 6 blocked the alleviation of EB extravasation at 7 days after thrombin injections (see Fig  4B; 
Discussion
The acute cerebral edema that occurs after ICH is mediated by thrombin. 1 Once ICH occurs in humans or animal models, thrombin is activated through the coagulation cascade and diffuses into the brain parenchyma. Thus, the intraventricular injections used here provide a model for the diffusion of thrombin into brain after ICH. Direct thrombin injections into the brain have been used widely to model this aspect of ICH.
3,4,10,11 One milliliter of whole blood produces ϳ260 to 360U of thrombin, and a 50L clot (used experimentally in rats) produces up to ϳ15U of thrombin. 1 Therefore, in this study we injected 20U of thrombin into the cerebral ventricle of the rat to get an approximate acute concentration of 35U/ml of thrombin in the cerebrospinal fluid (CSF), based on an estimated volume of CSF in a 300g rat of ϳ580L.
15
This dose was slightly more than the threshold (30U/ml) above which thrombin began to produce neuronal cell death in vitro as described in our previous studies.
11
The intraventricular thrombin injections caused reductions in BMVEC and perivascular astrocyte immunoreactivity, and disrupted the BBB as manifested by increased BBB permeability and increased cerebral water content 1 day later. The decreased BMVEC RECA-1 and astrocyte GFAP immunoreactivity could represent decreases of these proteins in injured cells, or death of the BMVECs and astrocytes. Whichever it is, thrombininduced injury to the BBB was blocked by acute admin- istration of hirudin and PP2. Hirudin is a direct peptidomimetic thrombin inhibitor, demonstrating that it is thrombin signaling that mediates the increased edema. However, thrombin inhibitors may not be good treatment targets for ICH, because these might affect the clotting and hemostatic functions of thrombin needed to halt progression of ICH. 16 We recently reported that nonspecific Src family kinase inhibitors (like PP2), which are less likely to affect coagulation, decreased glucose hypermetabolism and cell death around ICH and improved behavioral deficits after ICH. 11 ,17 Thus, we tested and have shown here that blocking Src family kinases with PP2 totally blocked the reductions in BMVEC and perivascular astrocyte immunoreactivity, and blocked increased BBB permeability and edema produced by thrombin. This can be explained by the fact that thrombin binding to thrombin receptors, called protease-activated receptors (PARs), 18 activates Src kinase family members. 19, 20 Thus, the current data suggest that thrombin-induced edema is mediated by the following pathway: thrombin 3 PAR 3 Src family kinase activation 3 BBB breakdown 3 increased BBB permeability and brain edema. Src family kinase members could mediate BBB permeability changes and edema by phosphorylating metalloproteinases, tight junction proteins, and other BBB proteins, 21, 22 and also via increased induction of vascular endothelial growth factor. 23 The data show that although the BBB is severely damaged by 1 day after thrombin injection, there is significant repair by 7 days, and apparent complete recovery of normal BBB permeability and brain water content by 14 days. By examining the time course of proliferating cells with BrdU, we show that the birth of BMVECs and perivascular astrocytes corresponds with the functional repair of the BBB-as manifested by decreased brain edema and decreased BBB permeability.
Because this observation only reveals a correlation, we sought to demonstrate a causal relationship between birth of BMVECs and astrocytes and BBB repair. To test this, we administered PP2 throughout the time when BBB repair was occurring (days 2 through 6) after the thrombin injections. We used PP2 because Src family kinase members play a major role in regulating the cell cycle. Src mutations result in uncontrolled cell growththat is, a tumor. Inhibiting Src family kinase members decreases astrocyte proliferation. 24 Moreover, blocking Src family kinases (c-Fyn) prevents BMVEC proliferation and tube-like structure formation of murine brain capillary endothelial cells. 25 Thus, we postulated that PP2 blockade of the birth of new BMVECs and perivascular astrocytes would prevent BBB repair. Indeed, the data show that administration of PP2 for days 2 through 6 after thrombin injections prolongs BBB permeability and prevents the resolution of brain edema that would normally occur by 7 days. Thus, the data support the hypothesis that the birth of BMVECs and perivascular astrocytes contributes to BBB repair. Our hypothesis that thrombin injury induced the birth of new astrocytes is in agreement with other studies that have described astrocytic proliferation in central nervous system disorders. 26 -28 In particular, activation of PAR1 triggers astrogliosis after brain injury, 27 and low doses of thrombin activate PAR1 to mediate proliferation of astrocytes via mitogen-activated protein kinase (MAPK) signaling pathways. 29 Thus, the thrombin-induced astrocyte proliferation pathway appears to be: thrombin 3 PAR1 3 Src kinsase 3 MAPK 3 astrocyte proliferation. Thrombin also promotes astrocyte survival at low concentrations via a separate pathway: thrombin 3 PAR1 3 Jun kinase 3 release of the chemokine growth related oncogene/cytokine-induced neutrophil chemoattractant-1.
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The primary evidence for BMVEC and astrocyte proliferation in this study is the incorporation of BrdU into the cells. Although BrdU can label cells that are undergoing DNA repair and cells that re-enter the cell cycle and eventually die, 31 In addition to the proliferating BMVEC and astrocytes, we detected a number of other BrdU ϩ cells located in the brain parenchyma close to the vessel wall. These could be newborn pericytes, inflammatory cells, or other cells that might respond to thrombin-induced injury to the neurovascular unit and disruption of the BBB. Further studies are needed to confirm the identity of these other newborn cells. BMVECs and astrocytes play a key role in the formation and maintenance of the BBB, and because the injury and proliferation of these cells in our study paralleled the repair of the BBB, the newborn BMVEC and astrocytes likely play an important role in the repair process. In culture, astrocytes contribute to tight junctions, 32 and astrocytic end feet have an important functional relationship with BMVECs. 6, 9, [33] [34] [35] Astrocytes are important for correct assembly of BMVECs and pericytes into tube-like structures in vitro. 36 Our data support the idea that the birth of new BMVECs and astrocytes is necessary to re-
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April, 2010establish a functional barrier and decrease BBB permeability and cerebral edema in vivo. The cell source of the newborn BMVECs and astrocytes was not examined in this study. Recent studies suggest that a number of "stem cells" or "progenitor cells" exist throughout the mammalian brain, and some of these are associated with vascular niches. 37 Such progenitor cells could serve as a source of newborn BMVECs, astrocytes, and other cells of the neurovascular unit that would play a major role in re-establishing the BBB, as appeared to be the case in this study. 38 Indeed, thrombin injections into the brain stimulate the birth of new neurons, 39 so it is reasonable to believe that the birth of other cell types also occurs after ICH and thrombin activation. Thus, the progenitor cells associated with the neurovascular niche are well situated to give birth to new cells needed to repair injury to the BBB. Because delayed inhibition of Src family kinases prevents repair of the BBB and is known to prevent proliferation of astrocytes and endothelial cells, we propose that Src family kinases mediated proliferation of newborn BMVECs and perivascular astrocytes located in the neurovascular niche, which repaired the damaged BBB. In addition, Src-mediated birth of all cells that constitute the neurovascular unit and regulate the barrier (BMVECs, astrocytes, pericytes, and neurons) may be required for the complete repair of the BBB after ICH/ thrombin-induced injury. This process may also occur after many other types of brain injury.
There are several limitations of the study. The loss of RECA-1 and GFAP immunostaining after thrombin injections could represent decreases of these proteins in surviving cells. Alternatively, the loss of the RECA-1 and GFAP staining could represent death of endothelial cells and astrocytes. The uncertainty in the interpretation of this finding does not affect the major conclusions of the study: acute BBB breakdown is blocked by a Src family kinase inhibitor; and repair of the BBB is mediated by Src-mediated proliferation of cells-likely including endothelial cells and astrocytes. The double-labeled BrdU-G-FAP and BrdU-RECA-1 stained cells were not confirmed using orthogonal confocal microscopy. This is not likely to be major problem, because the morphology of the double-labeled cells often was similar to the morphology of the stained nuclei. Lastly, chronic PP2 administration eliminated these perivascular double-labeled cells, supporting the interpretation that these are newborn endothelial cells and astrocytes (not shown).
Since a nonspecific Src family kinase inhibitor was used (PP2), the current study does not address which specific Src family members might mediate the effects reported here: Src itself, Fyn, Lyn, or others. It is even possible that different Src family members might mediate BBB breakdown and BBB repair.
